MGTA Insider Trading Activity and SEC Form 4 Filings
MGTA insider trading summary
No open-market insider purchases or sales of Magenta Therapeutics, Inc. (MGTA) have been reported on SEC Form 4 in the past 12 months.
Latest MGTA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Feb 8, 2023 | Third Rock Ventures GP IV, L.P. | 10% Owner | Sell | $1.2M (1,500,000 @ $0.82) |
| Feb 8, 2023 | Third Rock Ventures IV, L.P. | 10% Owner | Sell | $1.2M (1,500,000 @ $0.82) |
| Feb 8, 2023 | Trv Gp IV, LLC | 10% Owner | Sell | $1.2M (1,500,000 @ $0.82) |
| Feb 7, 2023 | Third Rock Ventures IV, L.P. | 10% Owner | Sell | $1.8M (2,200,000 @ $0.83) |
| Feb 7, 2023 | Third Rock Ventures GP IV, L.P. | 10% Owner | Sell | $1.8M (2,200,000 @ $0.83) |
| Feb 7, 2023 | Trv Gp IV, LLC | 10% Owner | Sell | $1.8M (2,200,000 @ $0.83) |
| Sep 16, 2021 | Lisa Olson | See Remarks | Sell | $39K (5,736 @ $6.73) |
| Sep 16, 2021 | David Wayne Nichols | Chief Technical Officer | Sell | $38K (5,694 @ $6.73) |
| Sep 16, 2021 | Caren Deardorf | Chief Commercial Officer | Sell | $42K (6,238 @ $6.73) |
| Sep 16, 2021 | Jason Gardner | See Remarks | Sell | $97K (14,340 @ $6.73) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.